BackXPhyto Therapeutics Overview

XPhyto Therapeutics Current Cash

Track XPhyto Therapeutics's current cash ($1.2M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$1.20M
↑ 28277.41% YoYΔ $1.20M vs prior year quarter

Peer trimmed avg / median

Loading

XPhyto Therapeutics Current Cash History

Loading

XPhyto Therapeutics vs. peers: Current Cash Comparison

Loading

XPhyto Therapeutics Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

XPhyto Therapeutics (4XT.DE) FAQ

XPhyto Therapeutics (4XT.DE) currently reports a current cash of $1.2M as of June 2026. That compares with $4.2K in the prior-year period — up 28277.4% year over year. Use the charts on this page to explore XPhyto Therapeutics's current cash history and peer comparisons.

XPhyto Therapeutics's current cash increased from $4.2K to $1.2M — a 28277.4% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

XPhyto Therapeutics reported $1.2M in current cash as of June 2026. That compares with $4.2K in the prior-year period — up 28277.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $1.2M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for XPhyto Therapeutics, and consider following 4XT.DE for alerts when major investors trade the stock.